TABLE 2.

Clinical trials with an artificial form of the phytate in the last 5 years.

References	Design	Treatment	Patients	Key effects
Perelló et al. (2018)	Clinical trialRandomizedDouble-blindplacebo-controlled	SNF472(2 mg/kg× 9 mg/kg)/weekDuration: 4 weeks	AdultHDn = 8	-Calcium phosphate crystal formation was lower in the plasma samples of HD patients receiving the SNF472 compared to the placebo control
Salcedo et al. (2019)	Clinical trialRandomizedDouble-blindplacebo-controlled	SNF472(3 × 1 10 mg/kg)/weekDuration: 5 weeks	AdultHDn = 8	-The hydroxyapatite crystallization was decreased significantly in the treatment group compared to the control group-No adverse effect
Raggi et al. (2020)	Clinical trialDouble-blindPlacebo-controlled	SNF472(3 mg× 300 mg, 600 mg)/weekDuration: 52 weeks	AdultRenal Diseasen = 274	-The progression of coronary artery and aortic valve calcification in patients was attenuated by SNF472 as compared to the placebo-controlled group
Bellasi et al. (2021)	Clinical TrialRandomizedDouble-blindPlacebo-controlled	SNF472	Adult	-Cardiovascular calcification was reduced in the SNF472 treated group as compared to the placebo-control
Bushinsky et al. (2021)	Clinical TrialRandomizedDouble-blindPlacebo-controlled	SNF472(3 mg × 300 mg, 600 mg)/weekDuration: 52 weeks	AdultHDn = 274	- BMD was decreased in all groups, especially in the 600 mg SNF472 group at the end of 52 weeks
Dold et al. (2020)	Clinical trialRandomizedSingle-blind	FeSO4, FePP and Fe-PA-HCP(1 mg × 4.2 mg)/dayDuration: 33 days	AdultHealthyn = 23	-Fe-PA-HCP, co-ingested with bouillon, has a promising effect on patients with iron-depleted women

BMD, bone mineral density; HD, hemodialyses; BMD, bone mineral density.